2026年8月19日 12:42 ET 发布 · 更新于 3 个月前 · 1 个来源
Moderna's mRNA cancer vaccine trial success leads to significant stock surge
Youtube
·
原始报道
Moderna's stock jumped over 140% following successful late-stage trial results for its mRNA cancer vaccine, marking a positive market event that contrasts with other market movements driven by debt and efforts to prop up bonds. Moderna is characterized as an 'accidental beneficiary from COVID' alongside Zoom and Peloton.
原文